Glycine N-methyltransferase (GNMT) is the main enzyme responsible for catabolism of excess hepatic S-adenosylmethionine (SAMe). GNMT is absent in hepatocellular carcinoma (HCC), messenger RNA (mRNA) levels are significantly lower in livers of patients at risk of developing HCC, and GNMT has been proposed to be a tumor-susceptibility gene for liver cancer. The identification of several children with liver disease as having mutations of the GNMT gene further suggests that this enzyme plays an important role in liver function. In the current study we studied development of liver pathologies including HCC in GNMTknockout (GNMT-KO) mice. GNMT-KO mice have elevated serum aminotransferase, methionine, and SAMe levels and develop liver steatosis, fibrosis, and HCC. We found that activation of the Ras and Janus kinase ( T he first steps in mammalian methionine metabolism are conversion to S-adenosylmethionine (SAMe) and transfer of the methyl group of SAMe to a large variety of substrates (including DNA, RNA, histones, and small molecules such as glycine, guanidinoacetate, and phosphatidylethanolamine) with the formation of S-adenosylhomocysteine (SAH), an inhibitor of many SAMe-dependent methyltransferases. 1 Although there are a large number of SAMe-dependent methyltransferases, 2 methylation of glycine by glycine Nmethyltransferase (GNMT) to form sarcosine (N-methylglycine) is one of the reactions that contribute most to total transmethylation flux. 3 The importance of GNMT is to remove excess SAMe and maintain a constant hepatic SAMe/SAH ratio to avoid aberrant methylation. 2 Consistent with this function, the activation of GNMT in rats by the administration of retinoic acid causes a reduction in plasma methionine and homocysteine levels, as well as in liver DNA methylation. 4,5 In GNMT-knockout (GNMT-KO) mice, liver SAMe content is elevated 35-fold, and the SAMe/SAH ratio increases about 100-fold, 6 and individuals with GNMT mutations, which leads to inactive forms of the enzyme, have elevated plasma levels of methionine and SAMe but a normal concentration of homocysteine. 7,8 GNMT is expressed in the liver, pancreas, and prostate 9 and is absent in hepatocellular carcinoma (HCC) 10 and down-regulated in the livers of patients at risk of Abbreviations: GNMT, HCC, hepatocellular carcinoma; H3K27me3, trimethylated Received September 10, 2007; accepted November 26, 2007. Supported by NIH grants AA12677, AA13847, and AT-1576 (to S.C.L. and J.M.M.); DK15289 (to C.W.), PN IϩD SAF 2005-00855, HEPADIP-EULSHM-CT-205, and ETORTEK 2005 (to J.M.M. and M.L.M.-C.); Program Ramón y Cajal (to M.L.M.-C.); and Fundación "La Caixa" (to M.L.M.-C., R.M., and A.M.A.).
Because plants are sessile, they have developed intricate strategies to adapt to changing environmental variables, including light. Their growth and development, from germination to flowering, is critically influenced by light, particularly at red (660 nm) and far-red (730 nm) wavelengths. Higher plants perceive red and far-red light by means of specific light sensors called phytochromes(A-E). However, very little is known about how light signals are transduced to elicit responses in plants. Here we report that nucleoside diphosphate kinase 2 (NDPK2) is an upstream component in the phytochrome signalling pathway in the plant Arabidopsis thaliana. In animal and human cells, NDPK acts as a tumour suppressor. We show that recombinant NDPK2 in Arabidopsis preferentially binds to the red-light-activated form of phytochrome in vitro and that this interaction increases the activity of recombinant NDPK2. Furthermore, a mutant lacking NDPK2 showed a partial defect in responses to both red and farred light, including cotyledon opening and greening. These results indicate that NDPK2 is a positive signalling component of the phytochrome-mediated light-signal-transduction pathway in Arabidopsis.
Methylation is a major biological process. It has been shown to be important in formation of compounds such as phosphatidylcholine, creatine, and many others and also participates in epigenetic effects through methylation of histones and DNA. The donor of methyl groups for almost all cellular methylation reactions is S-adenosylmethionine. It seems that the level of S-adenosylmethionine must be regulated in response to developmental stages and metabolic changes, and the enzyme glycine N-methyltransferase has been shown to play a major role in such regulation in mammals. This minireview will focus on the latest discoveries in the elucidation of the mechanism of that regulation. Discovery of S-Adenosylmethionine and Its VersatilityAdoMet 2 was discovered in 1951 by Cantoni as the "active methionine" used in the enzymatic transfer of the methyl group of methionine to nicotinamide to form N 1 -methylnicotinamide (1). With the exception of a few intracellular parasites that take up AdoMet from their hosts, AdoMet is formed from ATP and methionine by methionine adenosyltransferases present in all (or virtually all) cells of all organisms, including archaea, eubacteria, and eukaryotes. The reaction involves, initially, transfer of the adenosyl group of ATP to methionine, with the remainder of the ATP being converted to enzyme-bound tripolyphosphate. The latter compound is hydrolyzed to pyrophosphate and phosphate, which are then released (2). Being a sulfonium compound, AdoMet provides the large amounts of free energy (20 ϳkcal/mol) needed for methyl group transfers.AdoMet is possibly the most (or, compared with ATP, the second most) versatile compound in Nature. It is a source not only of methyl groups but, in diverse reactions in various organisms, provides methylene groups, four-carbon moieties, ribosyl groups, amino groups, and, after decarboxylation, threecarbon moieties for polyamines and ethylene (3). It may be converted to a 5Ј-deoxyadenosyl free radical that participates in a great variety of "radical SAM" reactions (4). AdoMet also functions as a regulator of many metabolic pathways in mammals, plants, and bacteria.In mammals, Ͼ90% of AdoMet is used for methylation reactions by at least 50 different methyltransferases (5). Methylation of both small molecules (e.g. phosphatidylethanolamine and guanidinoacetate) and macromolecules (DNA, RNA, histones, and other proteins) plays critical roles in cellular metabolism. Methylations of DNA and histones are major events in epigenetics. Therefore, the level of AdoMet must be carefully regulated to maintain cellular homeostasis. Recent evidence has established that GNMT plays a major role in maintaining normal AdoMet levels in mammals. GNMT Genes and ProteinsIn 1960, enzymatically catalyzed direct transfer of a methyl group from AdoMet to glycine (forming sarcosine) was demonstrated. The activity was found in liver extracts from guinea pig, rat, rabbit, and mouse, but the enzyme was not purified until 1972 when Heady and Kerr, upon finding that glycine was a better acce...
Background & Aims-Hepatic de-differentiation, liver development, and malignant transformation are processes in which the levels of hepatic S-adenosylmethionine (SAMe) are tightly regulated by two genes, MAT1A and MAT2A. MAT1A is expressed in the adult liver, whereas MAT2A expression is primarily extra-hepatic and is strongly associated with liver proliferation. The mechanisms that regulate these expression patterns are not completely understood. In silico analysis of the 3′ untranslated region of MAT1A and MAT2A revealed putative binding sites for the RNA-binding proteins AUF1 and HuR, respectively. We investigated the post-transcriptional regulation of MAT1A and MAT2A by AUF1, HuR and methyl-HuR in the aforementioned biological processes.
Non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease in most western countries. Current NAFLD diagnosis methods (e.g. liver biopsy analysis or imaging techniques) are poorly suited as tests for such a prevalent condition, from both a clinical and financial point of view. The present work aims to demonstrate the potential utility of serum NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript metabolic profiling in defining phenotypic biomarkers that could be useful in NAFLD management. A parallel animal model / human NAFLD exploratory metabolomics approach was employed, using ultra performance liquid chromatography-mass spectrometry (UPLC ® -MS) to analyze 42 serum samples collected from non-diabetic, morbidly obese, biopsy-proven NAFLD patients, and 17 animals belonging to the glycine N-methyltransferase knockout (GNMT-KO) NAFLD mouse model. Multivariate statistical analysis of the data revealed a series of common biomarkers that were significantly altered in the NAFLD (GNMT-KO) subjects in comparison to their normal liver counterparts (WT). Many of the compounds observed could be associated with biochemical perturbations associated with liver dysfunction (e.g. reduced Creatine) and inflammation (e.g. eicosanoid signaling). This differential metabolic phenotyping approach may have a future role as a supplement for clinical decision making in NAFLD and in the adaption to more individualized treatment protocols.
Three human cases having mutations in the glycine N-methyltransferase (GNMT) gene have been reported. This enzyme transfers a methyl group from S-adenosylmethionine (SAM) to glycine to form S-adenosylhomocysteine (SAH) and N-methylglycine (sarcosine) and is believed to be involved in the regulation of methylation. All three cases have mild liver disease but they seem otherwise unaffected. To study this further, gnmt deficient mice were generated for the first time. This resulted in the complete absence of GNMT protein and its activity in livers of homozygous mice. Compared to WT animals the absence of GNMT resulted in up to a 7-fold increase of free methionine and up to a 35-fold increase of SAM. The amount of SAH was significantly decreased (3 fold) in the homozygotes compared to WT. The ratio of SAM/SAH increased from 3 in WT to 300 in livers of homozygous transgenic mice. This suggests a possible significant change in methylation in the liver and other organs where GNMT is expressed.
Methionine adenosyltransferase 1A (MAT1A) and glycine N-methyltransferase (GNMT) are the primary genes involved in hepatic S-adenosylmethionine (SAMe) synthesis and degradation, respectively. Mat1a ablation in mice induces a decrease in hepatic SAMe, activation of lipogenesis, inhibition of triglyceride (TG) release, and steatosis. Gnmt deficient mice, despite showing a large increase in hepatic SAMe, also develop steatosis. We hypothesized that as an adaptive response to hepatic SAMe accumulation, phosphatidylcholine (PC) synthesis via the phosphatidylethanolamine (PE) N-methyltransferase (PEMT) pathway is stimulated in Gnmt−/− mice. We also propose that the excess PC thus generated is catabolized leading to TG synthesis and steatosis via diglyceride (DG) generation. We observed that Gnmt−/− mice present with normal hepatic lipogenesis and increased TG release. We also observed that the flux from PE to PC is stimulated in the liver of Gnmt−/− mice and that this results in a reduction in PE content and a marked increase in DG and TG. Conversely, reduction of hepatic SAMe following the administration of a methionine deficient diet reverted the flux from PE to PC of Gnmt−/− mice to that of wild type animals and normalized DG and TG content preventing the development of steatosis. Gnmt−/− mice with an additional deletion of perilipin2, the predominant lipid droplet protein, maintain high SAMe levels, with a concurrent increased flux from PE to PC, but do not develop liver steatosis. Conclusion These findings indicate that excess SAMe reroutes PE towards PC and TG synthesis, and lipid sequestration.
Deletion of glycine N-methyltransferase (GNMT), the main gene involved in liver S-adenosylmethionine (SAM) catabolism, leads to the hepatic accumulation of this molecule and the development of fatty liver and fibrosis in mice. To demonstrate that the excess of hepatic SAM is the main agent contributing to liver disease in GNMT knockout (KO) mice, we treated 1.5-month-old GNMT-KO mice for 6 weeks with nicotinamide (NAM), a substrate of the enzyme NAM N-methyltransferase. NAM administration markedly reduced hepatic SAM content, prevented DNA hypermethylation, and normalized the expression of critical genes involved in fatty acid metabolism, oxidative stress, inflammation, cell proliferation, and apoptosis. More importantly, NAM treatment prevented the development of fatty liver and fibrosis in GNMT-KO mice. Because GNMT expression is down-regulated in patients with cirrhosis, and because some subjects with GNMT mutations have spontaneous liver disease, the clinical implications of the present findings are obvious, at least with respect to these latter individuals. Because NAM has been used for many years to treat a broad spectrum of diseases (including pellagra and diabetes) without significant side effects, it should be considered in subjects with GNMT mutations. Conclusion: The findings of this study indicate that the anomalous accumulation of SAM in GNMT-KO mice can be corrected by NAM treatment leading to the normalization of the expression of many genes involved in fatty acid metabolism, oxidative stress, inflammation, cell proliferation, and apoptosis, as well as reversion of the appearance of the pathologic phenotype. (HEPATOLOGY 2010;52:105-114) Abbreviations: 5mC, 5-methyl-cytosine; a-SMA, a-smooth muscle actin; ADFP, adipose differentiation-related protein; COL1A1, pro-a1-collagen type I; CYP2E1, cytochrome P4502E1; CYP39A1, cytochrome P45039A1; CYP4A10, cytochrome P4504A10; CYP4A14, cytochrome P4504A14; CD36, fatty acid translocase CD36; ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GNMT, glycine N-methyltransferase; GSH, glutathione; HCC, hepatocellular carcinoma; IL6, interleukin-6; iNOS, inducible nitric oxide synthase; JAK, Janus kinase; KO, knockout; MAT, methionine adenosyltransferase; NAM, nicotinamide; NNMT, nicotinamide N-methyltransferase; PARP, poly(ADP-ribose) polymerase; PCR, polymerase chain reaction; PPAR, peroxisome proliferator-activated receptor; RASSF1A, Ras-association domain family/tumor suppressor-1A; SAH, S-adenosylhomocysteine; SAM, Sadenosylmethionine; SEM, standard error of the mean; SIRT1, sirtuin-1; SOCS1, suppressor of cytokine signaling-1; STAT, signal transducer and activator of transcription; TIMP-1, TIMP tissue inhibitor of metalloproteinase-1; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; UCP2, uncoupling protein-2; WT, wild-type.From the
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.